420 related articles for article (PubMed ID: 27479125)
1. The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study.
Theil G; Fischer K; Weber E; Medek R; Hoda R; Lücke K; Fornara P
PLoS One; 2016; 11(8):e0158354. PubMed ID: 27479125
[TBL] [Abstract][Full Text] [Related]
2. Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups.
Awe JA; Saranchuk J; Drachenberg D; Mai S
Urol Oncol; 2017 May; 35(5):300-309. PubMed ID: 28202223
[TBL] [Abstract][Full Text] [Related]
3.
Theil G; Boehm C; Fischer K; Bialek J; Hoda R; Weber E; Schönburg S; Kawan F; Fornara P
Oncol Lett; 2021 May; 21(5):357. PubMed ID: 33747214
[TBL] [Abstract][Full Text] [Related]
4. Analogous detection of circulating tumor cells using the AccuCyte
van der Toom EE; Groot VP; Glavaris SA; Gemenetzis G; Chalfin HJ; Wood LD; Wolfgang CL; de la Rosette JJMCH; de Reijke TM; Pienta KJ
Prostate; 2018 Mar; 78(4):300-307. PubMed ID: 29285777
[TBL] [Abstract][Full Text] [Related]
5. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer.
Resel Folkersma L; San José Manso L; Galante Romo I; Moreno Sierra J; Olivier Gómez C
Urology; 2012 Dec; 80(6):1328-32. PubMed ID: 23063057
[TBL] [Abstract][Full Text] [Related]
8. Molecular Profiling of Pooled Circulating Tumor Cells from Prostate Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device.
Yin C; Wang Y; Ji J; Cai B; Chen H; Yang Z; Wang K; Luo C; Zhang W; Yuan C; Wang F
Anal Chem; 2018 Mar; 90(6):3744-3751. PubMed ID: 29464943
[TBL] [Abstract][Full Text] [Related]
9. Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients.
Markou A; Lazaridou M; Paraskevopoulos P; Chen S; Świerczewska M; Budna J; Kuske A; Gorges TM; Joosse SA; Kroneis T; Zabel M; Sedlmayr P; Alix-Panabières C; Pantel K; Lianidou ES
Clin Chem; 2018 Feb; 64(2):297-306. PubMed ID: 29122836
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score.
Kolostova K; Broul M; Schraml J; Cegan M; Matkowski R; Fiutowski M; Bobek V
Anticancer Res; 2014 Jul; 34(7):3641-6. PubMed ID: 24982381
[TBL] [Abstract][Full Text] [Related]
11. Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients.
Kuske A; Gorges TM; Tennstedt P; Tiebel AK; Pompe R; Preißer F; Prues S; Mazel M; Markou A; Lianidou E; Peine S; Alix-Panabières C; Riethdorf S; Beyer B; Schlomm T; Pantel K
Sci Rep; 2016 Dec; 6():39736. PubMed ID: 28000772
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application.
Chen F; Wang S; Fang Y; Zheng L; Zhi X; Cheng B; Chen Y; Zhang C; Shi D; Song H; Cai C; Zhou P; Xiong B
Oncotarget; 2017 Jan; 8(2):3029-3041. PubMed ID: 27935872
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells predict survival in patients with metastatic prostate cancer.
Moreno JG; Miller MC; Gross S; Allard WJ; Gomella LG; Terstappen LW
Urology; 2005 Apr; 65(4):713-8. PubMed ID: 15833514
[TBL] [Abstract][Full Text] [Related]
15. Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis.
Cho H; Chung JI; Kim J; Seo WI; Lee CH; Morgan TM; Byun SS; Chung JS; Han KH
Cancer Sci; 2021 Feb; 112(2):859-870. PubMed ID: 33232539
[TBL] [Abstract][Full Text] [Related]
16. Tumorigenic potential of circulating prostate tumor cells.
Carvalho FL; Simons BW; Antonarakis ES; Rasheed Z; Douglas N; Villegas D; Matsui W; Berman DM
Oncotarget; 2013 Mar; 4(3):413-21. PubMed ID: 23530114
[TBL] [Abstract][Full Text] [Related]
17. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.
Kirby BJ; Jodari M; Loftus MS; Gakhar G; Pratt ED; Chanel-Vos C; Gleghorn JP; Santana SM; Liu H; Smith JP; Navarro VN; Tagawa ST; Bander NH; Nanus DM; Giannakakou P
PLoS One; 2012; 7(4):e35976. PubMed ID: 22558290
[TBL] [Abstract][Full Text] [Related]
19. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
[TBL] [Abstract][Full Text] [Related]
20. EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression.
Satelli A; Batth I; Brownlee Z; Mitra A; Zhou S; Noh H; Rojas CR; Li H; Meng QH; Li S
Oncotarget; 2017 Jul; 8(30):49329-49337. PubMed ID: 28521303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
